Discussion about this post

User's avatar
Krishna Patekar's avatar

The backtest point deserves more weight than the headline outperformance. A higher Sharpe ratio over 3, 5 and 10 years is not the same as maximising Bitcoin exposure, and the piece shows why: from the November 2021 cycle top, monthly dollar-cost averaging into Bitcoin still beat dollar-cost averaging into the enhanced funds on total return, while a one-time purchase lagged badly. That is a path-dependence warning. With a 95% equity and 5% Bitcoin starting mix, and a dividend drip of only about 1% on the S&P 500, the Bitcoin weight can drift down for a long stretch before new dividends rebuild it. So I would frame FEBQ and FIBT as volatility-managed equity products with a Bitcoin kicker, not as a substitute for a deliberate Bitcoin allocation, and judge them on drawdown and Sharpe rather than on whether they keep pace with Bitcoin in a strong run.

AlgoTradeAlert.com's avatar

The structure only rebalances when the Bitcoin sleeve gets too large, so the funds sell BTC into strength but only add through the roughly 1% S&P dividend stream. That asymmetry is a real limit on how much downside protection the wrapper gives.

No posts

Ready for more?